Chronic Leukemia Perspective

• Emerging Trends: Targeted Therapy for CLL   MD Anderson hematologists discuss recent developments in treatment options for chronic lymphocytic leukemia, including monoclonal antibodies, targeted therapies, and small-molecule inhibitors.
  Medscape TV, September 2019
• EHA 2019 Read clinically focused news coverage of key developments from EHA 2019
  Medscape Oncology, June 2019
• BSH 2019 Read clinically focused news coverage of key developments from BSH 2019
  Medscape Oncology, April 2019
• CAR T Cell Therapy: 'It's the Real World Now'   Drs Jacobson, Miklos, and Maus unveil 'provocative and exciting' research at ASH 2018 in CAR T cell therapy.
  Medscape Oncology, January 2019
• Venetoclax Shows Benefits Across a Range of Hematologic Cancers   From ASH 2018, Ann LaCasce and Jennifer Crombie from Dana-Farber discuss new trial data on venetoclax, a potent, selective inhibitor of BCL2.
  Medscape Oncology, December 2018
• Top News From ASH 2018: Slideshow Hot topics include practice change data on chronic lymphocytic leukemia, validation of the durability of CAR T cells, and a new standard of care in myeloma.
  Medscape News Slideshows, December 2018
• Chronic Myeloid Leukemia: Stopping Therapy the Right Way   The MD Anderson team discusses ways to increase patient compliance with TKI therapy as well as the correct way to stop TKI therapy electively for years at a time.
  Medscape TV, November 2018
• Time Out! A Close Look at Antibiotic Use in LTC Clinical cases illustrate the overuse of antibiotics to treat radiographic findings and lab reports, especially when prescribing over the phone.
  Medscape Infectious Diseases, October 2018
• Chronic Myeloid Leukemia: Critical Questions   The choice of first-, second-, and third-generation TKIs, with their varying toxicity profiles, and uncertainties about generic imatinib complicate frontline therapy.
  Medscape TV, September 2018
• EHA 2018 Read clinically focused news coverage of key developments from EHA 2018
  Medscape Oncology, June 2018
• Chronic Myeloid Leukemia: Rewriting Frontline Therapy   For 20 years, TKIs have been standard treatment in CML. But a growing number of options, including generic imatinib, raises questions regarding what is optimal frontline therapy for a given patient.
  Medscape TV, June 2018
• A 71-Year-Old Man With Malaise: USMLE Question A 71-year-old man presents with fatigue and malaise over the past three months. He also reports a 10 lbs weight loss. What's causing these symptoms?
  Osmosis, May 2018
• A 70-Year-Old Man With Splenomegaly: USMLE Question A 70-year-old man presents with splenomegaly. What is most likely to be found upon staining his cells?
  Osmosis, April 2018
• Maximizing Response in Acute Leukemia: Pearls From ASH 2017   Drs Cortes and DeAngelo highlight the most intriguing clinical trials presented in the field of leukemia at ASH 2017.
  Medscape Oncology, January 2018
• With So Many Options, Best CLL Treatment May Be a Clinical Trial Combination regimens in CLL are already impressive, but new combinations currently being evaluated have strong potential to be even better.
  Medscape Oncology, January 2018
• Top News From ASH 2017: Slideshow Hot topics include moving to newer oral anticoagulants for cancer patients with VTE, plus practice-changing results in chronic lymphocytic leukemia, multiple myeloma, and Hodgkin's lymphoma.
  Medscape News Slideshows, December 2017
• Merkel Cell Carcinoma: Not Just Another Skin Cancer Merkel cell expert Paul Nghiem, MD, PhD, explains how this rare but deadly condition differs from other forms of skin cancer.
  Medscape Dermatology, October 2017
• Safety With CAR T-Cell Therapy   Dr Stephan Grupp tells the 'inside story' of issues raised at the recent FDA Oncology Drug Advisory Committee meeting on CAR T-cell therapy.
  CHOP Expert Commentary, August 2017
• European Hematology Association (EHA) 2017 Congress Read clinically focused news coverage of key developments from EHA 2017.
  theheart.org on Medscape, June 2017
• In the Era of Novel Therapies, New CLL Markers Required Experts are finding that the International Prognostic Index for CLL may have significant limitations when used in the context of novel therapies.
  Medscape Oncology, February 2017